Free Articles, Free Web Content, Reprint Articles
Saturday, June 6, 2020
Free Articles, Free Web Content, Reprint ArticlesRegisterAll CategoriesTop AuthorsSubmit Article (Article Submission)ContactSubscribe Free Articles, Free Web Content, Reprint Articles

Lobaplatin combined with docetaxel treating breast cancer is safe and effective

The breast belongs to chemotherapy-sensitive tumors, combined with the efficacy of treating advanced or metastatic breast cancer is better than single anti-breast cancer drugs. Using docetaxel combine with lobaplatin treat breast cancer can achieve a good effect. 

According to pharmaceutical raw materials suppliers, docetaxel is one of the most effective drugs in the treatment of breast cancer, not only for first-line treatment of breast cancer, the effective rate of 43.9% for the first-line treating advanced breast cancer failed single-agent, clinical benefit rate is 85.4%. Cisplatin as first-line treatment of metastatic breast cancer, single-agent response rate was 50%, the efficiency of cisplatin in locally advanced breast cancer is greater than 80%, lobaplatin is the 3rd generation platinum anti-cancer drugs, anti-cancer activity is stronger, and the toxicity is lighter.

Docetaxel combined lobaplatin chemotherapy is not only have better efficacy for breast cancer also the toxicity can be tolerated. But should be paying attention to the platelet inhibition, for these emerged after chemotherapy in patients with thrombocytopenia, can consider the routine after chemotherapy of platelet-colony stimulating factor to prevent platelets reducing.

Drugs is used to treat a variety of diseases, but the adverse reaction is more or less harmful to human’s normal tissues, adversely affected organs. Common adverse drug reactions including the digestive system adverse reactions and liver toxicity, severe cases can lead to gastrointestinal mucosal ulcers and lesions of the liver tissue and even necrosis. For these conditions, taking some conditioning gastrointestinal tract, liver protection products can reduce the side effects of drugs such as the Hericium polysaccharides, Coriolus versicolor polysaccharide and serves the purpose of adjuvant therapy.

Breast cancer is one of the most common malignancy in women, the world each year to check out the number of breast cancer is increasing every year. The latest research estimates that 2009 will have more than 20 million women in the United States was diagnosed with breast cancer and 40,000 women died of breast cancer. Chinese breast cancer annual incidence rate is about 400,000, and increase 5% every year, has become one of the countries with the fastest growth rate of breast cancer incidence. At the same time, the breast cancer with recurrence and multi-channel transfer characteristics, is one of the cause of death in patients.

Treatments of advanced breast cancer is in combination with chemotherapy, docetaxel is one of the most active drugs in breast cancer chemotherapy. Docetaxel is belong to taxanes through the essentially "freeze" the internal skeleton of the cell inhibition of tumor cell differentiation microtubule cytoskeleton, microtubules in the cell cycle and timely assembly and spin-off phenomenon. Docetaxel promote the assembly of microtubules and prevents microtubule spin-off, leading to the arrangement of the microtubule bundle abnormal formation of the aster, spindle loss of normal function, leading to cell death. Studies by docetaxel manufacturer show that in metastatic breast cancer, docetaxel monotherapy in anthracycline treatment failure rate was 34% and 58%, combination chemotherapy effective rate is 60% to 80%.

Epirubicin is the same isomers of adriamycin, the mechanism of action is directly embedded in the nuclear DNA of alkali on interference of the transcription process, preventing the formation of the mRNA, thus inhibiting DNA and RNA synthesis. Compared with doxorubicin, the efficacy is equal or slightly higherArticle Submission, but less toxic to the heart.


Source: Free Articles from


Home Repair
Home Business
Self Help

Page loaded in 0.124 seconds